# US 2015/0104428 A1 · Compositions and Treatment Methods for Mesenchymal Stem Cell-Induced Immunoregulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104428 A1
- Document ID: US20150104428A1
- Status: Published application
- Kind: A1
- Application number: 14/389,322
- Filed: 2013-03-29
- Published: 2015-04-16
- Earliest claimed: 2012-03-30
- Assignees: University of Southern California
- Applicants: University of Southern California
- Inventors: Songtao Shi; Kentaro Akiyama; Chider Chen
- Web page: https://patentgrep.com/patent/US20150104428A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Mesenchymal Stem Cells (MSCs), including bone marrow-derived MSCs (BMMSCs) expressing Fas and FasL, and secreting MCP-1 are disclosed. Also disclosed are methods for upregulating regulatory T cells in a subject by administering MSCs, including BMMSCs. Also disclosed are methods for treating systemic sclerosis or colitis in a subject by administering MSCs, including BMMSCs.

## Claims

### Claim 1

A method of treating a patient comprising administering a composition comprising a therapeutically effective amount of an isolated and purified population of mesenchymal stem cells (MSCs) to the patient, wherein said MSCs: a) express Fas, b) express FasL and c) secrete MCP-1.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein said MSCs are bone marrow MSCs (BMMSCs).

### Claim 4 (depends on 3)

The method of claim 3, wherein said BMMSCs are human BMMSCs (hBMMSCs).

### Claim 5 (depends on 1)

The method of claim 1, wherein said MSCs are allogenic.

### Claim 6 (depends on 1)

The method of claim 1, wherein from 1×103 to 1×107 of said MSCs per kg body weight of the patient are administered.

### Claim 7 (depends on 1)

The method of claim 1, wherein from 1×10 to 1×107 of said MSCs per kg body weight of the patient are administered.

### Claim 8 (depends on 1)

The method of claim 1, wherein said MSCs are administered by infusion.

### Claim 9 (depends on 1)

The method of claim 1, wherein said MSCs are administered by transplantation.

### Claim at position 10

10-22. (canceled)

### Claim 23

An isolated and purified population of MSCs, wherein said MSCs a) express Fas, b) express FasL and c) secrete MCP-1.

### Claim 24 (depends on 23)

The isolated and purified population of MSCs of claim 23, wherein the MSCs are bone marrow mesenchymal stem cells (BMMSCs).

### Claim 25 (depends on 24)

The isolated and purified population of MSCs of claim 24, wherein the BMMSCs are human BMMSCs.

### Claim 26 (depends on 23)

The isolated and purified population of MSCs of claim 23, wherein said MSCs have been transfected with a vector comprising a gene for human FasL operably linked to a promoter, and wherein FasL is overexpressed from said vector.

### Claim 27 (depends on 26)

The isolated and purified population of MSCs of claim 26, wherein said MSCs have been transfected with a vector comprising a gene for human Fas operably linked to a promoter, and wherein Fas is overexpressed from said vector.

### Claim at position 16

28-43. (canceled)

### Claim 44 (depends on 23)

A pharmaceutical composition comprising the isolated and purified population of MSCs of claim 23 dispersed in a pharmaceutically acceptable carrier.

### Claim 45 (depends on 1)

The method of claim 1, wherein the patient is a patient with an inflammatory disease and/or an autoimmune disease.

### Claim 46 (depends on 1)

The method of claim 1, wherein the patient is a patient with systemic sclerosis.

### Claim 47 (depends on 1)

The method of claim 1, wherein the patient is a patient with colitis.

### Claim 48 (depends on 1)

The method of claim 1, wherein the method produces immune tolerance to immunotherapies in the patient.

### Claim 49 (depends on 1)

The method of claim 1, wherein said administration causes an upregulation in the level of regulatory T cells in the peripheral blood of the patient.
